. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002 Nov;59(11):1729-34. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on Primary Papers and News

  1. The ability to accurately identify patients with MCI who will progress to AD would be a great asset to clinical trials of drugs designed to reduce rates of progression of the disease. There is already evidence that phosphorylated tau appears in the CSF of MCI patients and may be used as a marker for who will progress to AD. There are two papers to this effect (Buerger et al., 2002a and de Leon et al., 2002), which were not cited by these authors. It would appear that phosphorylated tau is a superior marker to total tau in CSF, as it does not show elevations in concentration in the absence of AD pathology (Buerger et al., 2002b;).

    References:

    . CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002 Aug 27;59(4):627-9. PubMed.

    . Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002 Nov 29;333(3):183-6. PubMed.

    . Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002 Aug;59(8):1267-72. PubMed.

    View all comments by Peter Davies

This paper appears in the following:

News

  1. Spinal Taps for Tau Tests
  2. Biomarker Bonus: Phospho-Tau/Aβ Ratio Increase Sensitivity